HomeCompareITCI vs MRK

ITCI vs MRK: Dividend Comparison 2026

ITCI yields 1.52% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $34.9K in total portfolio value
10 years
ITCI
ITCI
● Live price
1.52%
Share price
$131.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.9K
Annual income
$167.32
Full ITCI calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — ITCI vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodITCIMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ITCI + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ITCI pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ITCI
Annual income on $10K today (after 15% tax)
$128.91/yr
After 10yr DRIP, annual income (after tax)
$142.22/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,186.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ITCI + MRK for your $10,000?

ITCI: 50%MRK: 50%
100% MRK50/50100% ITCI
Portfolio after 10yr
$39.3K
Annual income
$4,982.73/yr
Blended yield
12.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ITCI
Analyst Ratings
14
Buy
9
Hold
Consensus: Buy
Price Target
$98.50
-25.3% upside vs current
Range: $70.00 — $132.00
Altman Z
38.0
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ITCI buys
0
MRK buys
0
No recent congressional trades found for ITCI or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricITCIMRK
Forward yield1.52%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$21.9K$56.8K
Annual income after 10y$167.32$9,798.13
Total dividends collected$1.6K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$98.50$128.54

Year-by-year: ITCI vs MRK ($10,000, DRIP)

YearITCI PortfolioITCI Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,852$151.66$11,206$366.19$354.00MRK
2$11,765$153.81$12,650$502.35$885.00MRK
3$12,745$155.85$14,407$694.19$1.7KMRK
4$13,794$157.78$16,585$967.82$2.8KMRK
5$14,920$159.61$19,342$1,363.89$4.4KMRK
6$16,125$161.33$22,913$1,947.19$6.8KMRK
7$17,417$162.96$27,662$2,823.89$10.2KMRK
8$18,801$164.50$34,159$4,173.35$15.4KMRK
9$20,283$165.95$43,337$6,308.80$23.1KMRK
10$21,870$167.32$56,776$9,798.13$34.9KMRK

ITCI vs MRK: Complete Analysis 2026

ITCIStock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Full ITCI Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ITCI vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ITCI vs SCHDITCI vs JEPIITCI vs OITCI vs KOITCI vs MAINITCI vs JNJITCI vs ABBVITCI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.